Division of Pulmonary and Critical Care Medicine, Department of Medicine and the Cardiovascular Research Institute, University of California San Francisco, San Francisco, California.
Center for Genes, Environment, and Health and.
Am J Respir Crit Care Med. 2020 Jul 1;202(1):83-90. doi: 10.1164/rccm.202003-0821OC.
Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ACE2 (angiotensin-converting enzyme 2), and TMPRSS2 (transmembrane protease serine 2) mediate viral infection of host cells. We reasoned that differences in ACE2 or TMPRSS2 gene expression in sputum cells among patients with asthma may identify subgroups at risk for COVID-19 morbidity. To determine the relationship between demographic features and sputum ACE2 and TMPRSS2 gene expression in asthma.: We analyzed gene expression for ACE2 and TMPRSS2, and for ICAM-1 (intercellular adhesion molecule 1) (rhinovirus receptor as a comparator) in sputum cells from 330 participants in SARP-3 (Severe Asthma Research Program-3) and 79 healthy control subjects. Gene expression of ACE2 was lower than TMPRSS2, and expression levels of both genes were similar in asthma and health. Among patients with asthma, male sex, African American race, and history of diabetes mellitus were associated with higher expression of ACE2 and TMPRSS2. Use of inhaled corticosteroids (ICS) was associated with lower expression of ACE2 and TMPRSS2, but treatment with triamcinolone acetonide did not decrease expression of either gene. These findings differed from those for ICAM-1, where gene expression was increased in asthma and less consistent differences were observed related to sex, race, and use of ICS. Higher expression of ACE2 and TMPRSS2 in males, African Americans, and patients with diabetes mellitus provides rationale for monitoring these asthma subgroups for poor COVID-19 outcomes. The lower expression of ACE2 and TMPRSS2 with ICS use warrants prospective study of ICS use as a predictor of decreased susceptibility to SARS-CoV-2 infection and decreased COVID-19 morbidity.
新型冠状病毒病(COVID-19)是由严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)引起的。ACE2(血管紧张素转化酶 2)和 TMPRSS2(跨膜丝氨酸蛋白酶 2)介导病毒感染宿主细胞。我们推测,哮喘患者痰液细胞中 ACE2 或 TMPRSS2 基因表达的差异可能确定 COVID-19 发病率的高危亚组。为了确定哮喘患者的人口统计学特征与痰液 ACE2 和 TMPRSS2 基因表达之间的关系:我们分析了 SARP-3(严重哮喘研究计划-3)的 330 名参与者和 79 名健康对照者痰液细胞中 ACE2 和 TMPRSS2 的基因表达,以及 ICAM-1(细胞间黏附分子 1)(鼻病毒受体作为比较器)。ACE2 的基因表达低于 TMPRSS2,并且这两种基因在哮喘和健康人群中的表达水平相似。在哮喘患者中,男性、非裔美国人和糖尿病史与 ACE2 和 TMPRSS2 的高表达相关。吸入皮质激素(ICS)的使用与 ACE2 和 TMPRSS2 的表达降低相关,但曲安奈德治疗并未降低这两种基因的表达。这些发现与 ICAM-1 的发现不同,在哮喘中 ICAM-1 的基因表达增加,并且观察到与性别、种族和 ICS 使用相关的差异不太一致。ACE2 和 TMPRSS2 在男性、非裔美国人和糖尿病患者中的高表达为监测这些哮喘亚组的 COVID-19 不良结局提供了依据。ICS 使用与 ACE2 和 TMPRSS2 表达降低相关,这需要对 ICS 使用作为 SARS-CoV-2 感染易感性降低和 COVID-19 发病率降低的预测因素进行前瞻性研究。